# Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

> **NCT03882437** · PHASE1 · UNKNOWN · sponsor: **Rocket Pharmaceuticals Inc.** · enrollment: 7 (actual)

## Conditions studied

- Danon Disease

## Interventions

- **BIOLOGICAL:** RP-A501

## Key facts

- **NCT ID:** NCT03882437
- **Lead sponsor:** Rocket Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-17
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-03-24
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882437, "Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03882437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*